Advertisement
Advertisement
U.S. Markets close in 27 mins
Advertisement
Advertisement
Advertisement
Advertisement

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9500+0.0400 (+1.37%)
As of 03:33PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.9100
Open2.9000
Bid2.9400 x 800
Ask3.0000 x 800
Day's Range2.8800 - 3.0000
52 Week Range2.5200 - 4.4600
Volume89,099
Avg. Volume55,906
Market Cap107.02M
Beta (5Y Monthly)0.10
PE Ratio (TTM)N/A
EPS (TTM)-0.8510
Earnings DateApr 25, 2022 - Apr 29, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    BrainStorm to Announce Second Quarter Results and Provide a Corporate Update

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, August 15, 2022.

  • PR Newswire

    BrainStorm Announces Presentations at June 2022 Scientific Conferences

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at forthcoming ALS and MS scientific conferences in June 2022. Insights into the ALS Phase 3 primary endpoint leveraging ENCALS model patient prognosis trajectories will be presented as a scientific poster at the European Network to Cure ALS (ENCALS) meeting in Edinburgh, Scotland June 1-3, 2022. At the Consortium of Multiple Sclerosis Centers

  • Zacks Small Cap Research

    BCLI: Anticipating News on How NurOwn® Will be Advanced Forward…

    By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Anticipating News on How NurOwn® Will be Advanced Forward in ALS BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is developing NurOwn as a treatment for patients with amyotrophic lateral sclerosis (ALS). The company recently published results from the Phase 3 trial of NurOwn in Muscle and Nerve that showed while

Advertisement
Advertisement